We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

123 hedge funds and large institutions have $648M invested in Theravance Biopharma in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more call options, than puts

Call options by funds: $9.48M | Put options by funds: $4.19M

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

70% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 27

14% more capital invested

Capital invested by funds: $568M → $648M (+$80.2M)

9% more funds holding

Funds holding: 113 → 123 (+10)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.54% less ownership

Funds ownership: 84.39% → 83.85% (-0.54%)

Holders
123
Holders Change
+10
Holders Change %
+8.85%
% of All Funds
2.12%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
46
Reduced
27
Closed
13
Calls
$9.48M
Puts
$4.19M
Net Calls
+$5.29M
Net Calls Change
+$5.24M

Top Buyers

1
WAM
Weiss Asset Management
Massachusetts
+$11.4M
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$6.53M
3
Two Sigma Investments
Two Sigma Investments
New York
+$6.12M
4
Millennium Management
Millennium Management
New York
+$6.1M
5
NM
Newtyn Management
New York
+$4.29M

Top Sellers

1
WP
Woodline Partners
California
-$19.9M
2
PWAM
Park West Asset Management
California
-$11.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$5.05M
4
MAP
Madison Avenue Partners
New York
-$2.41M
5
Voloridge Investment Management
Voloridge Investment Management
Florida
-$2.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
1
Baupost Group
Massachusetts
$136M – – –
WAM
2
Weiss Asset Management
Massachusetts
$75.6M +$11.4M +1,219,622 +20%
MAP
3
Madison Avenue Partners
New York
$71.1M -$2.41M -257,358 -4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$60.9M -$5.05M -538,673 -8%
BlackRock
5
BlackRock
New York
$51.8M +$794K +84,787 +2%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$25.8M -$1.48M -158,063 -6%
NM
7
Newtyn Management
New York
$25.3M +$4.29M +458,035 +22%
PWAM
8
Park West Asset Management
California
$19.5M -$11.7M -1,253,900 -40%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$16.1M +$1.94M +206,801 +15%
State Street
10
State Street
Massachusetts
$15.1M -$96.4K -10,287 -0.7%
C
11
Chescapmanager
Maryland
$11.8M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$10.9M +$482K +51,423 +5%
Bank of America
13
Bank of America
North Carolina
$9.34M +$2.3M +245,648 +36%
Jacobs Levy Equity Management
14
Jacobs Levy Equity Management
New Jersey
$8.39M -$297K -31,700 -4%
Two Sigma Advisers
15
Two Sigma Advisers
New York
$7.06M +$6.53M +696,600 New
Two Sigma Investments
16
Two Sigma Investments
New York
$6.62M +$6.12M +652,870 New
Millennium Management
17
Millennium Management
New York
$6.6M +$6.1M +650,558 New
Goldman Sachs
18
Goldman Sachs
New York
$6.32M +$373K +39,830 +7%
Morgan Stanley
19
Morgan Stanley
New York
$6.07M +$1.92M +205,080 +52%
Northern Trust
20
Northern Trust
Illinois
$6.07M +$28.8K +3,069 +0.5%
Norges Bank
21
Norges Bank
Norway
$5.53M – – –
Charles Schwab
22
Charles Schwab
California
$5.32M +$201K +21,439 +4%
PAMS
23
Pictet Asset Management (Switzerland)
Switzerland
$3.76M +$1.02M +108,952 +42%
RCMNY
24
Rubric Capital Management (New York)
New York
$3.61M +$3.34M +356,100 New
OMC
25
Oasis Management Company
Cayman Islands
$3.01M +$2.78M +296,960 New
1
2 3 4 5

TBPH Hedge Fund Activity: Q3 2022 in Review

123 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2022, worth a combined $648M — up 14% from $568M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new TBPH positions and 13 closed out — a net gain of 10 holders — while 46 added to existing stakes and 27 trimmed.

The largest buyer was Weiss Asset Management, adding an estimated $11.4M. The largest seller was Woodline Partners, cutting an estimated $19.9M.

  • 123 institutional investors held Theravance Biopharma (TBPH) as of Q3 2022, up from 113 in Q2 2022.
  • Funds reported $648M of Theravance Biopharma stock for Q3 2022, up 14% quarter-over-quarter.
  • 23 funds opened new Theravance Biopharma positions in Q3 2022 and 13 closed out, a net change of +10 holders.
  • The largest Theravance Biopharma buyer in Q3 2022 was Weiss Asset Management, an estimated $11.4M added.
  • The largest Theravance Biopharma seller in Q3 2022 was Woodline Partners, an estimated $19.9M sold.

Based on aggregated 13F filings for Q3 2022.